Digital health and home-based medical technologies are transforming long-term care—especially in mental health, where relapse after treatment remains a significant challenge. A new international study shows just how effective this shift can be.
A major global research effort, the PSYLECT study, has demonstrated remotely supervised, at-home brain stimulation therapy can prevent relapses of major depressive disorder in 75% of patients. Published in the Journal of Affective Disorders, this study offers strong evidence that accessible, non-drug treatments can help people maintain recovery in the months after initial therapy, which is a period where relapse rates have historically reached 85%.
The study followed 71 participants who had completed their primary depression treatment. For six months, they used at-home tDCS (transcranial direct current stimulation) twice a week, paired with online behavioral support. Researchers tracked their progress without requiring ongoing clinic visits. At the end of the period, only six participants experienced a return of depressive symptoms, and most maintained stable recovery with home-based therapy alone.
Here is how this can help:
- Close the treatment gap by providing a reliable relapse-prevention tool that doesn’t require frequent in-person appointments.
- Increase accessibility and reduce costs, as patients can receive care from home while achieving outcomes comparable to in-clinic treatment.
- Enhance scalability, helping clinics reduce wait times and free up clinician capacity for higher-need cases.
Looking to the future, this represents a major step toward a future where long-term depression care is more accessible, more scalable, and more sustainable.